Hereditary thrombophilia: One of the models of molecular medicine;Hereditární trombofilie - Jeden z modelů molekulární medicíny

Klinicka Biochemie a Metabolismus

Volumn 13, Issue 2, 2005, Pages 68-76

  Raušová, Eva ^a   Hadacova I ^b   Macek, M ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antithrombin III; Hereditary thrombophilia; Mutation FII G20210A; Mutation FV Leiden; Protein C; Protein S

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ALLELE; ARTICLE; GENETIC DISORDER; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; MUTATION; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 27644446131     PISSN: 12107921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Venter, J. C., Adams, M. D., Myers, E. W. et al. The sequence of the human genome. Science, 2001, 291, 1, p. 304-351.
2. Preissner, K. T. Biochemistry and physiology of blood coagulation and fibrinolysis. Hemostaseologie, 2004, 24, 2, p. 84-93.
3. Doplen, D. The plasminogen (fibrinolytic) system. Thromb. Haemost., 1999, 82, p. 259-270.
4. Burke, W., Atkins, D., Gwinn, M., Guttmacher, A., Haddaw, J. et al. Genetic test evaluation: Information needs of clinitians, policy makers, and the public. Amer. J. Epid., 2002, 156, 4, p. 311-318.
5. Dahlback, B., Carlsson, M., Svensson, P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc. Natl. Acad. Sci. USA, 1993, 90, p. 1004-1008.
6. Koster, T., Rosendaal, F. R., de Ronde, H., Briet, E., Vandenbroucke, J. P., Bertina, R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet, 1993, 342, p. 1503-1506.
7. Legnani, C., Palareti, G., Biagi, R. et al. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br. J. Haematol., 1996, 93, p. 694-699.
8. Kapiotis, S., Quehenberger, P., Jilma, B. et al. Improved characteristics of APC-resistance assay: Coatest APC resistance by predilution of samples with factor V deficient plasma. Am. J. Clin. Pathol., 1996, 106, p. 588-593.
9. Poort, S. R., Rosendaal, F. R., Reitsma, P. H., Bertina, R. M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 1996, 15, p. 3698-3703.
10. Gehring, N. H., Frede, U., Neu-Yilik, G., Hundsdoerfer, P., Vetter, B. et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet., 2001, 28, p. 389-392.
11. Griffin, J. H., Evatt, B., Zimmerman, T. S., Kleiss, A. J., Wideman, C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest., 1981, 68, p. 1370-1373.
12. Tait, R. C., Walker, I. D., Reitsma, P. H. et al. Prevalence of protein C deficiency in the healthy population. Thromb. Haemost., 1995, 73, p. 87-93.
13. Beauchamp, N. J., Dykes, A. C., Parikh, N., Campbell Tait R., Daly, M. E. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br. J. Haematol., 2004, 125, p. 647-654.
14. Kvasnička, J. et al. Trombofilie atrombotické stavy v klinické praxi. Praha: Avicenum Grada 2003, p. 51.
15. Williamson, D., Brown, K., Luddington, R. et al. Factor V Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood, 1998, 91, p. 1140-1144.
16. Chan, W. P., Lee, C. K., Kwong, Y. L. et al. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood, 1998, 91, p. 1135-1139.
17. Castoldi, E., Rosing, J., Girelli, D. et al. Mutations in the R2 FV gene affect the ratio between two FV isoforms in plasma. Thromb. Haemost., 2000, 83, p. 362-365.
18. Faloni, E. M., Franchi, F., Bucciarelli, P. et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood, 1999, 94, p. 3062-3066.
19. Le Flem, L, Mennen, L, Aubry, M. L, Aiach, M, Scarabin, P. et al. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler. Thromb. Vasc. Biol., 2001, 21, p. 445-451.
20. Biguzzi, E., Merati, G., Liaw, P. C., Bucciarelli, P., Oganesyan, N. et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function Thromb. Haemost., 2001, 86, p. 945-948.
21. Tybjaerg-Hansen, A., Agerholm-Larsen, B., Humphries, S. E., Abildgaard, S., Schnohr, P., Nordestgaard, B. G. A common mutation (G(-455)-to-A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: a study of 9,127 individuals based on the Copenhagen City Heart Study. J. Clin. Inves.t, 1997, 99, p. 3034-3039.
22. Schmidt, H., Schmidt, R., Niederkorn, K., Horner, S., Becsagh, P. et al. Beta-fibrinogen gene polymorphism (C148 > T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler. Thromb. Vasc. Biol., 1998, 18, p. 487-492.
23. Mrozikiewicz, P. M., Cascorbi, I., Ziemer, S., Laule, M., Neosel, C. et al. Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J. Am. Coll. Cardiol., 2000, 36, p. 1520-1525.
24. Iacoviello, L., Di Castelnuovo, A., De Knijff, P., D'Orazio, A., Amore, C. et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. Med., 1998, 338, p. 79-85.
25. Aleksic, N., Ahn, C., Wang, Y. W., Juneja, H., Folsom, A. R. et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol., 2002, 22, p. 348-352.
26. Zidane, M., de Visser, M. C., ten Wolde, M., Vos, H. L., de Monye, W. et al. V. Frequency of the TAFI -438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb. Haemost., 2003, 90, p. 439-445.
27. Gardemann, A., Lohre, J., Katz, N., Tillmanns, H., Hehrlein, F. W., Haberbosch, W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb. Haemost., 1999, 82, p. 1121-1126.
28. Sartori, M. T., Danesin, C., Saggiorato, G., Tormene, D., Simioni, P. et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost., 2003, 9, 4, p. 299-307.
29. Jannes, J., Hamilton-Bruce, M. A., Pilotto, L., Smith, B. J., Mullighan, C. G. Et al. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke, 2004, 35, p. 1090-1094.
30. Juhan-Vague, I., Morange, P. E., Aubert, H., Henry, M., Aillaud, M. F. et al. HIFMECH Study Group Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol., 2002, 22, p. 867-873.
31. Knoefler, R., Ludwig, K., Kostka, H., Kuhlisch, E., Siegert, G., Suttorp, M. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients. Semin. Thromb. Hemost., 2003, 29, p. 575-583.
32. Boushey, C. J, Beresford, S. A, Omenn, G. S, Mottulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA, 1995, 274, p. 1049-1057.
33. Gastadnes, M, Rudiger, N, Rasmussen, K, Ingerslev, J. Familial thrombophilia associated with homozygosity for the cystathionine β-synthase 833T-C mutation. Arterioscler. Thromb. Vasc. Biol., 2000, 20, p. 1392-1395.
34. DeLoughery, T. G., Evans, A., Sadeghi, A. et al. A common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late onset vascular disease. Circulation, 1996, 94, p. 3074-3078.
35. Kluijtmans, L. A., van den Heauvel, L. P. W., Boers G. H. et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet., 1996, 58, p. 35-41.
36. Brattstrom, L., Wilcken, D. E., Ohrvik, J., Brudin, L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation, 1998, 98, p. 2250 till 2556.
37. Pastinen, T., Perola, M., Ninini, P. et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum. Mol. Genet., 1998, 7, p. 1453-1462.
38. A2 polymorphism: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol., 1999, 19, p. 1142-1147.
39. A2 polymorphism and efficacy of aspirin. Lancet, 1998, 351, p. 1353.
40. Santoso, S., Kunicki, T. J., Kroll, H., Haberbosch, W., Gardemann, A. Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood, 1999, 93, p. 2449-2453.
41. Drift, S. A, Hampton, K. K, Sorrell, J. A, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br. J. Haematol., 1999, 106, p. 771-776.
42. Kroll, H., Gardemann, A., Fechter, A., Haberbosch, W., Santoso, S. The impact of the glycoprotein la collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction. Thromb. Haemost., 2000, 83, p. 393-396.
43. Arnaud, E., Nicaud, V., Poirier, O. et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler. Thromb. Vasc. Biol., 2000, 20, p. 585-592.
44. Heit, J. A., Silverstein, M. D., Mohr, D. N. et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost., 2001, 86, p. 452-463.
45. Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med., 1995, 332, p. 912-917.
46. Selingsohn, U, Lubetsky, A. Genetic susceptibility to venous thrombosis. N. Engl. J. Med., 2001, 344, p. 1222-1231.
47. Grandone, E., Margaglione, M., Colaizzo, D. Genetic subseptibility to pregnancy-related venous thrombembolism: roles of factor V Leiden, prothrombin G 20210A, and methylentetrahydrofolate reduktase C677T mutations. Am. J. Obstet. Gynecol., 1998, 179, p. 1324-1328.
48. Gerhart, A., Scharf, R. E., Beckmann, M. W. Prothrombin and factor V mutations in women with history of thrombosis dutiny pregnancy and puerperium. N. Engl. J. Med., 2000, 342, p. 374-380.
49. Friedrich, P. W., Sanson, B. J., Simioni, P. Frequency of pregnancy-related venous thrombembolism in anticoagulant factor deficient women: implication for prophylaxis. Ann. Intern. Med., 1996, 125, p. 955-960.
50. Presto, F. E., Rosendaal, F. R., Walker, I. D. Increased fetal loss in women with heritable thrombophilia. Lancet, 1996, 348, p. 913-916.
51. Kupferminc, M. J., Eldor, A., Steinman, N. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med., 1999, 340, p. 9-13.
52. Press, R. D., Bauer, K. A., Kujovich, J. L., Heit J. L. Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders. Archives of Pathology and Laboratory Medicine, 2002, 126, p. 1304-1318.